RT Journal Article
SR Electronic
T1 Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.06.21267342
DO 10.1101/2021.12.06.21267342
A1 FitzGerald, Richard
A1 Dickinson, Laura
A1 Else, Laura
A1 Fletcher, Thomas
A1 Hale, Colin
A1 Amara, Alieu
A1 Walker, Lauren
A1 Penchala, Sujan Dilly
A1 Lyon, Rebecca
A1 Shaw, Victoria
A1 Greenhalf, William
A1 Bullock, Katie
A1 Lavelle-Langham, Lara
A1 Reynolds, Helen
A1 Painter, Wendy
A1 Holman, Wayne
A1 Ewings, Sean
A1 Griffiths, Gareth
A1 Khoo, Saye
YR 2022
UL http://medrxiv.org/content/early/2022/03/02/2021.12.06.21267342.abstract
AB ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001).Competing Interest StatementSK has received research funding from ViiV Healthcare, Gilead Sciences, and Merck for the Liverpool HIV Drug Interactions programme and for clinical studies unrelated to the submitted work. GG has received funding from Jannsen-Cilag, Novartis, Astex, Roche, Heartflow, Bristol Myers Squibb, BioNtech; grants and personal fees from AstraZeneca; and personal fees from Celldex, unrelated to the submitted work. WG has received funding from the Wellcome Trust. WH is a cofounder, owner and advisor of/to Ridgeback Biotherapeutics. WP is employed by Ridgeback Biotherapeutics.Clinical TrialNCT04746183Funding StatementThis work was funded by the University of Liverpool. The AGILE platform infrastructure is supported by the Medical Research Council (grant number MR/V028391/1) and the Wellcome Trust (grant number 221590/Z/20/Z). AGILE CST-2 molnupiravir trial was supported by Ridgeback Biotherapeutics. We acknowledge National Institute for Health Research (NIHR) infrastructure funding for the Liverpool Clinical Research Facility and the Southampton Clinical Trials Unit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UK Medicines and Healthcare product Regulatory Agency (MHRA; EudraCT 2020 001860 27) and West Midlands Edgbaston Research Ethics Committee (20/WM/0136) and all individuals provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed and presented in the manuscript are available upon reasonable request to the authors